|
Mouse monoclonal antibody Anti-Human FBL
|
|
|
|
|
| This gene product is a component of a nucleolar small nuclear ribonucleoprotein (snRNP) particle thought to participate in the first step in processing preribosomal RNA. It is associated with the U3, U8, and U13 small nuclear RNAs and is located in the dense fibrillar component (DFC) of the nucleolus. The encoded protein contains an N-terminal repetitive domain that is rich in glycine and arginine residues, like fibrillarins in other species. Its central region resembles an RNA-binding domain and contains an RNP consensus sequence. Antisera from approximately 8% of humans with the autoimmune disease scleroderma recognize fibrillarin. [NCBI Entrez Gene Summary] |
|
|
|
|
|
|
Western blot analysis of immunized recombinant protein, using anti-FBL monoclonal antibody.
Arrow indicates the region of immunized recombinant protein carrying 50-200 amino acids. |
|
|
|
| Antibody Concentration |
100 μg/ml (1.0 ml) |
| Host Species |
Human |
| Preparation |
This antibody was purified using protein G column chromatography from culture supernatant of hybridoma cultured in a medium containing bovine IgG-depleted (approximately 95%) fetal bovine serum. |
| Sterility |
Filtered through a 0.22 μm membrane. |
| Alternate Names |
FIB, FLRN, RNU3IP1 |
| Accession No. |
NM_001436 |
| Purchase |
Ordering information
|
|
|
|
|
| Caution must be taken to avoid contact with skin or eyes. In such a case, rinse thoroughly at once with water. Do not ingest, inhale, or swallow. Seek medical attention immediately. Wear appropriate protective clothing such as laboratory overalls, safety glasses and gloves. It is strongly advised that this product should be handled by people who have been well trained in laboratory techniques and that it is handled with care pursuant to the principles of good laboratory practice. All chemicals are deemed potentially harmful. The vial is prone to fall over. Use caution, especially when the lid is off . |
|
|
|
FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.
|
|
|
|
|
close
